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Abstract
Background: L-carnitine (LC) plays an important physiologic role in lipid metabolism. To date, no clinical study has
been performed to examine the effect of LC supplementation on the lipid status of coronary artery disease (CAD)
patients. The aim of this study was to investigate the lipid lowering effects of LC supplementation (1000 mg/d) in
CAD patients.
Methods: CAD patients were identified by cardiac catheterization as having at least 50 % stenosis of one major
coronary artery. Forty-seven subjects were recruited and randomly assigned to the placebo (n = 24) and to the LC
(n = 23) groups. The intervention was administered for 12 weeks. The levels of LC, lipid profiles, and antioxidant
enzyme activity (superoxide dismutase, SOD) were measured.
Results: The subjects in the LC group had significantly higher SOD activity (20.7 ± 4.2 versus 13.1 ± 2.9 U/mg of
protein, P < 0.01), high density lipoprotein-cholesterol (1.34 ± 0.42 vs. 1.16 ± 0.24 mmol/L, HDL-C, P = 0.03), and
apolipoprotein-A1 (Apo-A1, 1.24 ± 0.18 vs. 1.12 ± 0.13 g/L, P = 0.02) than those in the placebo group at week 12.
Triglyceride (TG) level was slightly significantly reduced (1.40 ± 0.74 vs. 1.35 ± 0.62 mmol/L, P = 0.06) and the level of
LC was negatively correlated with TG and apolipoprotein-B (Apo-B), and positively correlated with HDL-C and
Apo-A1 after LC supplementation. Additionally, SOD activity was significantly negatively correlated with lipid profiles
(total cholesterol, TG, and Apo-B) after supplementation.
Conclusion: LC supplementation at a dose of 1000 mg/d showed significantly increased in HDL-C and Apo-A1
levels and a slight decrease in TG levels but no other changes in other lipids in CAD patients, and this
lipid-lowering effect may be related to its antioxidant ability. Further studies should be conducted to define an
optimal dose of LC for lipid-lowering in patients with CAD.
Trial registration: Clinical Trials.gov Identifier: NCT01819701
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Background
L-carnitine (LC) plays an important physiologic role in
lipid metabolism. LC may carry long-chain fatty acids
across the inner mitochondrial membrane for β-
oxidation and adenosine triphosphate (ATP) produc-
tion [1, 2]. Recent studies have demonstrated that LC is
not only a transporter of lipids but is also an
antioxidant [3, 4]. LC appears to interfere with the for-
mation of reactive oxygen species, through its ferrous
ion metal-chelating ability, thus stabilizing the free rad-
icals formed on the α-carbon by conjugation [4, 5]. In
addition to its antioxidant activity, LC also exhibits
anti-inflammatory properties [6–8]. LC may inhibit the
nuclear factor-kappa B pathway through the suppres-
sion of reactive oxygen species formation [9–11]. Whereas
coronary artery disease (CAD) is associated with higher
levels of oxidative stress and inflammation and hyperlipid-
emic status [12], it may be helpful to administer LC to
CAD patients given its physiological functions.
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A number of clinical studies have been conducted
to examine the lipid-lowering effects of LC supple-
mentation in patients with renal disease [7, 8, 12–17],
diabetes [18–20], or hyperlipidemia [21, 22], however,
the results regarding the lipid-lowering effects of LC
supplementation are inconsistent due to different dis-
ease statuses. To date, no clinical study has been per-
formed to examine the effect of LC supplementation
on the lipid status of CAD patients. Therefore, the
purpose of this study was to investigate the effect of




A single-blind, randomized, parallel, placebo-controlled
trial was conducted. CAD patients were diagnosed by
cardiac catheterization (at least 50 % stenosis of one
major coronary artery) or by percutaneous translumi-
nal coronary angioplasty (PTCA) for stable condition.
We excluded the patients with diabetes, liver, or
renal diseases, along with those undergoing aceno-
coumarol, thyroid hormone, warfarin, and a high
dose of statin therapy [Atorvastatin (Lipitor) or Rosu-
vastatin (Crestor), 30-40 mg/d] or currently using
vitamin supplements. The study was approved by the
Institutional Review Board of Taichung Veterans
General Hospital, Taiwan and the clinical trial was
registered at Clinical Trials.gov (NCT01819701). This
clinical trial started recruiting subjects at January
2013, and the last subject was completed in February
2014. Each subject provided written informed con-
sent to participate in the study. A total of 47 CAD
patients were recruited to this study and randomly
assigned to the placebo (n = 24) or to the LC (1000
mg/day, n = 23) group. The supplements, placebo
(starch) and LC capsules were provided by New
Health Taiwan Co., Ltd (Taichung, Taiwan). At the
beginning of the study, the investigators instructed
the subjects to take two capsules daily (LC supple-
ments 500 mg b.i.d). To monitor the subject compli-
ance, we asked the subjects to return the supplied
bag of capsules every 4 weeks to verify the capsule
count. The intervention was administered for 12
weeks. The sampling and trial profiles along with the
number of subjects who completed the study in each
group are presented in Fig. 1.
At baseline, we measured the subjects’ blood pressure,
body weight, height, and waist circumference, and then
calculated the body mass index (kg/m2). General obesity
was defined as body mass index ≥ 27 kg/m2 [23], and
central obesity was defined as waist circumferences ≥ 90
cm. Dietary intakes were assessed using 24-h recall diet-
ary records at baseline. The dietary records were ana-
lyzed using the Nutritionist Professional software
package (E-Kitchen Business Corp., Taiwan).
Assessed for eligibility (n = 47)
Lost to follow-up (n = 5)
- Failure to return
Placebo group (n = 24)
Analysed (n = 20)





Analysed (n = 19)
Lost to follow-up (n=3)
- Failure to return
Fig. 1 Consort flow diagram
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Lipid profiles, L-carnitine, and antioxidant enzyme activity
measurements
The fasting blood specimens were collected in vacutai-
ner tubes without anticoagulant (Becton Dickinson,
Rutherford, NJ, USA). The samples were centrifuged at
3,000 rpm for 15 minutes at 4 °C, and the serum was
separated. Serum total cholesterol (TC), triacylglycerol
(TG), low density lipoprotein-cholesterol (LDL-C), and
high density lipoprotein-cholesterol (HDL-C) were
measured using an automated biochemical analyzer
(Hitachi-7180E, Tokyo, Japan). The levels of apolipo-
protein A-1 (Apo-A1) and apolipoprotein-B (Apo-B)
were measured using the polyethylene glycerol (PEG)
enhanced immunoturbidimetric assay method (Siemens
Healthcare Diagnostics Inc., New York, USA). The
level of LC was measured by the enzyme-linked im-
munosorbent assay (ELISA) method using commer-
cially available kits (Cusabio, Wuhan, China) according
to the instructions made available by the suppliers.
The antioxidant enzyme activity (superoxide dis-
mutase, SOD) were measured in the fresh red blood
cells (RBCs) samples. The RBCs were washed with
normal saline after removing the plasma, and then
diluted with 25x sodium phosphate buffer for meas-
urement. The methods for measuring SOD activity
have been described previously [24]. The protein
content of the plasma and RBCs was determined
based on the biuret reaction of the bicinchoninic acid
assay (BCA kit, Thermo, Rockford, IL, USA). SOD
values were expressed as U/mg of protein. All of the
analyses were performed in duplicate.
Statistical analysis
Means and standard deviations (s.d.) were calculated for
all data. Kolmogorov-Smirnov test was used to examine
the normal distribution of variables. Student’s t-test or
the Mann-Whitney rank sum test was used to compare
mean values for continuous variables between the pla-
cebo and LC groups. Paired t-test or Wilcoxon signed
rank test was used to compare the data before and after
supplementation within the group. For categorical re-
sponse variables, differences between the two groups
were assessed by the Chi-square test or Fisher's exact
test. Simple linear regressions were used to examine
the correlations between the levels of LC (as a
dependent variable) and lipid profiles after supplemen-
tation. Pearson correlations were used to examine the
correlations between the antioxidant enzyme activity
and lipid profiles after LC supplementation and the
correlations between the changes (week 12-0, △) in
antioxidant enzyme activity and lipid profiles. Statis-
tical significance was set at P < 0.05. All statistical ana-
lyses were performed using SigmaPlot software
(version 12.0, Systat, San Jose, CA, USA).
Results
Characteristics of the subjects at baseline
A total of 39 CAD subjects completed the 12-week
interventional study (Placebo, n = 19; LC, n = 20). The
baseline characteristics of the subjects are shown in
Table 1. The means and s.d. for age, blood pressure, and
dietary intakes as well as the percentages of general
obesity and central obesity were not significantly differ-
ent between the two groups at baseline.
Effects of LC supplementation on the levels of LC, SOD
activity, and lipid profiles
The subjects in the LC group had significantly increased
LC level (40.0 ± 12.0 versus.35.2 ± 12.0 μmol/L, P = 0.02)
and SOD activity (20.7 ± 4.2 versus 13.1 ± 2.9 U/mg of
protein, P < 0.01) compared with those in the placebo
group at week 12 as well as after LC supplementation
(LC, 33.6 ± 13.6 to 40.0 ± 12.0 μmol/L, P = 0.04; SOD,
14.8 ± 2.9 to 20.7 ± 4.2 U/mg of protein, P < 0.01). The
lipid profiles after supplementation are shown in Fig. 2.
The subjects in the LC group had significantly higher
level of HDL-C (1.34 ± 0.42 vs. 1.16 ± 0.24 mmol/L, P =
0.03) and Apo-A1 (1.24 ± 0.18 vs. 1.12 ± 0.13 g/L, P =
0.02) than those in the placebo group at week 12. After
Table 1 Baseline characteristics of the subjects
Placebo (n = 19) LC (n = 20)
Mean s.d. Mean s.d
Gender (male) 19 20
Age (y) 72.7 10.1 71.9 10.6
SBP (mmHg) 127.3 6.0 128.4 10.4
DBP (mmHg) 74.5 4.4 72.3 4.7
General obesitya (%) 36.8 30.0
Central obesitya (%) 84.2 65
Smokingb (n, %) 3 (15.8 %) 4 (20.0 %)
Drinkingc (n, %) 3 (15.8 %) 3 (15.0 %)
Dietary intake
Energy (kcal/day) 1501.4 63.7 1534.2 41.6
Protein (g/day, % of total calories) 54.2 (14.2) 11.2 51.1 (12.9) 6.9
Fat (g/day, % of total calories) 43.3 (26.4) 9.7 43.2 (23.8) 10.6
SFA (g/day) 11.7 5.3 10.6 5.4
PUFA (g/day) 14.0 3.5 15.9 3.6
MUFA (g/day) 13.3 3.8 13.0 4.9
Carbohydrate (g/day, % of
total calories)
225.3 (60.3) 16.3 236.7 (63.5) 24.7
aGeneral obesity was defined as body mass index ≥ 27 kg/m2 and central
obesity was defined as waist circumferences ≥ 90 cm. bSmoking: the individual
currently smokes one or more cigarettes per day. cDrinking: the individual
regularly drinks one or more drinks per day
DBP diastolic blood pressure; LC L-carnitine; MUFA monounsaturated fatty
acids; PUFA polyunsaturated fatty acids; SBP systolic blood pressure; SFA satu-
rated fatty acids
Lee et al. Lipids in Health and Disease  (2016) 15:107 Page 3 of 8
LC supplementation, the level of TG was slightly re-
duced but did not achieve statistical significance
(1.40 ± 0.74 vs. 1.35 ± 0.62 mmol/L, P = 0.06, respect-
ively). However, no significant change in the levels of
TC, LDL-C, and Apo-B after 12 weeks of LC supple-
mentation. Notably, the level of Apo-A1 was de-
creased in the placebo group after 12 weeks
intervention (1.20 ± 0.12 vs. 1.12 ± 0.13 g/L, P = 0.05);
however, the result was not statistically significant.
Correlations between the levels of lipid profiles and LC
after supplementation
The correlations between the levels of lipid profiles
and LC after supplementation and these results are
Fig. 2 Levels of lipids profiles after supplementation
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shown in Fig. 3. The level of LC was significantly nega-
tively correlated with TG (β = -0.14, P = 0.01). Although
not statistically significant, LC level correlated with
Apo-B (β = -0.02, P = 0.08), HDL-C (β = 0.07, P = 0.07)
and Apo-A1 (β = 0.01, P = 0.09) after 12 weeks of
supplementation.
Correlations between the SOD activity and lipid profiles
after LC supplementation
The correlations between the antioxidant enzyme ac-
tivity and lipid profiles after LC supplementation are
shown in Table 2. SOD activity was significantly negatively
correlated with TC (r = -0.34, P = 0.03), TG (r = -0.53, P <
0.01), and Apo-B (r = -0.32, P < 0.05) after 12 weeks of LC
supplementation. Furthermore, we assessed the correla-
tions between the changes (week 12-0, △) in antioxidant
enzyme activity and lipid profiles (Table 3). There was a
significant correlation between the changes level of SOD
activity and the changes in TC (r = -0.41, P < 0.01), LDL-C
(r = -0.45, P < 0.01), and Apo-B (r = -0.32, P < 0.01).
Discussion
Significant lipid-lowering effects of LC supplementa-
tion have been demonstrated in hemodialysis patients
[16, 17]. Naini et al. treated chronic hemodialysis pa-
tients with oral LC supplementation at doses of 750
mg/d and 1000 mg/d for 8 weeks and 16 weeks, re-
spectively. LC supplementation at a dose of 750 mg/d
significantly decreased levels of lipid (TC, TG, and
LDL-C) [17], whereas LC supplementation at a dose of
1000 mg/d significantly decreased levels of TC and TG
and increased the level of HDL-C [16]. LC may in-
crease the mitochondrial transport of fatty acids and
reduce fatty acid availability for lipid synthesis [25]. LC
has also improved the levels of lipid in CAD given that
LC is a lipid transporter. In this study, we observed
that LC administered at a dose of 1000 mg/d for 12
weeks correlated with decreased lipid profile (TG) levels
and increased levels of HDL-C and Apo-A1. Our previous
studies demonstrated that LC supplementation at a dose
of 1000 mg/d was significantly associated with increased
Fig. 3 Correlations between the levels of lipids profiles and L-carnitine after supplementation
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antioxidant capacity in CAD patients [26]. In addition, the
level of LC was significantly positively correlated with
antioxidant enzymes activity (SOD, β = 0.72, P < 0.01) and
reduced oxidative stress and inflammatory status in the
patients with CAD after supplementation [26, 27]. In this
study, we observed no significant correlation between LC
and lipids levels or between SOD activity and lipid levels
at baseline. Instead, antioxidant enzyme activity (SOD)
was significantly negatively correlated with lipid levels
(TC, TG, and Apo-B) after LC supplementation (Table 2).
As a result, wehypothesize that the effect of LC supple-
mentation on lipids (TG, HDL-C, and Apo-A1) may be
related to its antioxidant capacity.
Apolipoproteins, such as Apo-B and Apo A-1, are the
major apolipoproteins associated with LDL-C and HDL-
C, respectively [28]. In this study, we observed a signifi-
cant increase in the levels of Apo-A1 and HDL-C, and
the level of LC was slightly negatively correlated with
Apo-B after supplementation. However, no significant
change in the levels of TC and LDL-C were noted after
LC supplementation. In a clinical study, Malaguarnera et
al. investigated diabetes patients using a higher dose of
LC supplementation of 2000 mg/d for 12 weeks and ob-
served significant decreases in the levels of TC, TG,
LDL-C, oxidized LDL-C, and Apo-B, and increases in
the levels of HDL-C and Apo-A1 [20]. Hyperlipidemia is
a contributor to CAD; thus, we considered that if the
disease has already developed, the lipid-lowering effect
of LC supplementation at a dose of 1000 mg/d may not
be sufficient. Although LC at a dose of 1000 mg/d can
significantly increase the antioxidant activity [26], a
higher dose of LC (>1000 mg/d) administration could be
considered in anti-hyperlipidemic strategies [29, 30].
In the present study, TG level decreased after supple-
mentation, but the reduction did not achieve statistical
significance, which may have been attributed to the
stable CAD subjects and the limited number of subjects
(Placebo, n = 13; LC, n = 8) with hyperlipidemia (a ratio
of TC to HDL ≥ 5.0, TG ≥ 1.7 mmol/L, or LDL-C ≥ 3.4
mmol/L) [31]. Due to the small number of subjects hav-
ing hyperlipidemia in the LC group, the detection of the
lipid-lowering effects in these subjects may have been
limited. Because higher oxidative stress and inflamma-
tion status are early events in the evolution of hyperlip-
idemia [32, 33], we suggest that an antioxidant supply
(such as LC) may help prevent or delay the develop-
ment of CAD [26, 27]. The lipid-lowering effects of a
clinically relevant degree of LC supplementation might
be related to its dosage. Further studies should be con-
ducted to define an optimal dose of LC for lipid-
lowering in patients with CAD and explore whether it
could be used as a nutraceutical adjuvant in the cases
of dyslipidemia [34].
The strength of this study is that it is the first clinical
study to investigate the lipid-lowering effects of LC
supplementation in CAD patients, and we measured
the levels of LC, lipid profiles, and antioxidant enzyme
activity. This study provides direct evidence to clarify
the relationship among the levels of LC, lipid, and anti-
oxidant ability; however, longer intervention studies
with larger sample sizes should be performed to con-
firm the lipid-lowering effects after LC intervention in
patients with hyperlipidemia. There are some limita-
tions of the present study that should be mentioned.
First, the number of participants was small; however,
we performed the post hos calculations to examine the
statistical power for lipid profiles. The statistical power
of the differences of TG, HDL-C, and Apo-A1 were
0.97, 0.86, and 0.86, respectively. Second, a few of the
subjects had hyperlipidemia in the LC group; thus, the
detection of the lipid-lowering effects in these subjects
may have been limited. Moreover, an optimal dose of
LC for lipid-lowering should be defined. Further studies
should also investigate the effect of LC on NADPH oxi-
dase activity, HMG-CoA reductase activity and TG syn-
thesis to clarify if LC lowers lipids by enhancing
Table 3 Correlations between the changes (week 12-0, △) in
antioxidant enzyme activity and lipid profiles
△SOD (U/mg protein)
ra (P values)
△TC (mmol/L) −0.41 (< 0.01)
△TG (mmol/L) −0.11 (0.34)
△LDL-C (mmol/L) −0.45 (< 0.01)
△HDL-C (mmol/L) −0.04 (0.77)
△Apo-A1 (g/L) −0.09 (0.44)
△Apo-B (g/L) −0.32 (< 0.01)
acorrelation coefficients
Apo apolipoprotein; HDL-C high density lipoprotein-cholesterol; LC L-carnitine;
LDL-C low density lipoprotein-cholesterol; SOD superoxide dismutase; TC total
cholesterol; TG triglycerides
Table 2 Correlations between the antioxidant enzyme activity
and lipid profiles after L-carnitine supplementation
SOD (U/mg protein)
ra (P values)
TC (mmol/L) −0.34 (0.03)
TG (mmol/L) −0.53 (< 0.01)
LDL-C (mmol/L) −0.15 (0.36)
HDL-C (mmol/L) 0.11 (0.52)
Apo-A1 (g/L) −0.18 (0.29)
Apo-B (g/L) −0.32 (< 0.05)
acorrelation coefficients
Apo apolipoprotein; HDL-C high density lipoprotein-cholesterol; LC L-carnitine;
LDL-C low density lipoprotein-cholesterol; SOD superoxide dismutase; TC total
cholesterol; TG triglycerides
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mitochondrial fatty acid oxidation or by reducing oxi-
dative stress.
Conclusion
In conclusion, LC supplementation at a dose of 1000
mg/d exhibited significant increases in HDL-C and Apo-
A1 levels and a slight decrease in TG levels, but no
other changes in other lipids were noted in CAD pa-
tients. This lipid-lowering effect may be related to its
antioxidant ability.
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